# Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT06960395** · PHASE1 · RECRUITING · sponsor: **Vir Biotechnology, Inc.** · enrollment: 450 (estimated)

## Conditions studied

- Solid Tumor Malignancies
- EGFR Positive Solid Tumors
- EGFR

## Interventions

- **DRUG:** VIR-5525
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06960395
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2029-08
- **Final completion:** 2029-08
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06960395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06960395, "Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06960395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*